MSR
ALXN

Main Street Research’s Alexion Pharmaceuticals ALXN Stock Holding History

Main Street Research’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,900
Closed -$267K – 116
2017
Q3 		$267K Sell
1,900
-600
-24% -$81.5K 0.04% 97
2017
Q2 		$304K Buy
+2,500
New +$291K 0.05% 103

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Main Street Research's ALXN Position: Q4 2017 in Review

Main Street Research sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 1,900 shares — an estimated $267K sold.

Main Street Research first reported a position in ALXN in Q2 2017 and held it in 2 quarters. The position peaked at $304K in Q2 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Main Street Research reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Main Street Research sold 1,900 Alexion Pharmaceuticals shares in Q4 2017, an estimated $267K.
  • Main Street Research first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Main Street Research's Alexion Pharmaceuticals position peaked at $304K in Q2 2017.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Main Street Research's 13F filing for Q4 2017, filed 5 Feb 2018.